Recent News

• 06.04.2026 - BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
• 06.02.2026 - BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
• 05.18.2026 - BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
• 05.13.2026 - BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
• 04.22.2026 - BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
• 03.30.2026 - BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

Recent Filings

• 06.04.2026 - EX-99.1 EX-99.1
• 06.04.2026 - 8-K Current report
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 8-K Current report
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2026 - 4 Statement of changes in beneficial ownership of securities